Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Starboard Value
Pharma
Thumbs-up on BMS-Celgene deal ends months of activist outrage
With a shareholder vote in favor of the BMS-Celgene marriage, the combined company will get its chance to prove it's worth the $74 billion price.
Arlene Weintraub
Apr 12, 2019 10:39am
Starboard ends BMS proxy war after advisories back Celgene deal
Apr 1, 2019 11:02am
Could proxy advisers sway votes against BMS-Celgene merger?
Mar 21, 2019 11:51am
Without 'smoking gun,' BMS, Celgene deal will close: analyst
Mar 19, 2019 12:29pm
Could a Celgene patent dispute tank the BMS deal?
Mar 13, 2019 11:23am
Does Bristol have a plan B if activists scuttle Celgene buy?
Mar 11, 2019 12:12pm